

22 Nov 2021 | Analysis

Over The Counter 22 November 2021: CHC Spin Outs, Supply Chain Issues And Other Q3 Trends

by [David Ridley](#)

In this episode, HBW Insight's US and EU editors analyse Q3 OTC business trends, including why the biggest pharmaceutical companies in the world are spinning out their consumer health businesses to create new standalone firms and what's causing the supply chain troubles that are driving up OTC product prices.

[Click here to explore this interactive content online](#) ✨

Further Reading

[J&J Rides Standalone Consumer Health Track](#)

[Bausch + Lomb IPO Will Open Tap Further For Paying Down Bausch Health Debt](#)

[J&J Has 18.2% OTC Drug Sales Increase In Hand, But Not Decision On Talc Business Bankruptcy Plan](#)

[Perrigo Feels Chill From Q3 Results Due To 'Unfulfilled' Demand On Supply Chain Disruptions](#)

[Church & Dwight Chews On Strong Growth For Vitafusion As Consumers Stick To Category](#)

[Prestige Links Sales Growth To Retailer, Consumer Supply-Chain Fears](#)

[Sanofi Catching Up To Market Growth Rates As Q3 Sales Rise Double Digits](#)

[GSK Raises Product Prices in US And Europe As Costs Rise](#)

[Reckitt Raises Guidance Following Sharp Improvement In Cold & Flu Sales](#)

[Successful Innovation And Supplement Gains Drive 'Exceptional' Q3 For Bayer](#)

Further Listening

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.